See a Demo

Category: Blog

TrialAssure cubes divider
How Daiichi Sankyo Accelerated Plain Language Summary Development with TrialAssure LINK AI

How Daiichi Sankyo Accelerated Plain Language Summary Development with TrialAssure LINK AI

by Staff Writer | January 2026

Posted in Blog, Case Studies
Read More
TrialAssure Establishes Physical Presence in The Netherlands

TrialAssure Establishes Physical Presence in The Netherlands to Advance Clinical Trial Transparency and Data Sharing Across Europe

by Staff Writer | January 2026

Posted in Blog, News
Read More
Typing on keyboard

Experts Share Real-World Lessons to Applying AI in Medical Writing

by Staff Writer | December 2025

Posted in Blog
Read More
TrialAssure Officially Granted New Patent for Date Offset Anonymization Technology by U.S. Patent and Trademark Office

TrialAssure Officially Granted New Patent for Date Offset Anonymization Technology by U.S. Patent and Trademark Office

by Staff Writer | December 2025

Posted in Blog, News
Read More
Chris Hurley

Respected Data Science Industry Leader Chris Hurley Joins TrialAssure Advisory Leadership Team to Strengthen Data Strategy and Innovation

by Staff Writer | December 2025

Posted in Blog, News
Read More
How TrialAssure is Building Better DSURs with Purpose-Built Prompts, Smarter Sources, and a Proven Approach | pharma, biotech, life sciences, medical device

How TrialAssure is Building Better DSURs with Purpose-Built Prompts, Smarter Sources, and a Proven Approach 

by Zach Weingarden | November 2025

Posted in Blog
Read More
TrialAssure Introduces Enhanced Architectural Techniques to Improve Accuracy, Visibility, Traceability, and Control Across its AI Platform for Pharma and Biotech Innovative application architecture gives users clearer insight into AI responses, improves output reliability, and strengthens data alignment across LINK AI®, ANONYMIZE®, and REGISTRY® CANTON, Mich. (October 7, 2025) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced the launch of its new enhanced content search and sourcing capability, a technical upgrade designed to boost accuracy, transparency, and reliability across its suite of AI-powered tools. This advancement enables a more structured way for artificial intelligence (AI) to interpret, segment, and retrieve information from source documents, enabling users to gain more precise insights and greater control over the content. TrialAssure has introduced an integrated framework that leverages AI Large Language Models (LLMs) to process and manage content more effectively. This framework emphasizes efficient document ingestion and chunking, optimized embedding and indexing, structured information storage, and advanced AI prompt design and engineering. These techniques replace the out-of-the-box indexing and retrieval approaches and improve the visibility and traceability of AI responses, giving users greater confidence and a more efficient approach to generating structured and regulated documents in the life sciences arena. This also creates a more flexible and tailored experience, allowing AI models to separate, label, and group source material with greater specificity. For instance, information used to create clinical narratives can now be isolated by individual trial participants to eliminate cross-contamination and improve document fidelity. “Giving the pharma and biotech industry clarity into how AI reaches its outputs was a technical challenge at first, but it is our usability promise,” said Zach Weingarden, MS, Director of AI Technology & Applications, TrialAssure. “We are focused on raising the standard for how AI can operate transparently in highly regulated environments like life sciences.”

TrialAssure Introduces Enhanced Architectural Techniques to Improve Accuracy, Visibility, Traceability, and Control Across its AI Platform for Pharma and Biotech

by Staff Writer | October 2025

Posted in Blog, News
Read More
Is Now the Time for Pharma and Biotech to Act with AI or Should the Industry Wait for a Better Model? The integration of artificial intelligence (AI) into pharmaceutical and biotechnology workflows has accelerated significantly in recent years. According to peer-reviewed research by the Tufts Center for the Study of Drug Development, et al, more than 65 percent of pharmaceutical and biotechnology companies, contract research organizations (CROs), and data and technology vendors servicing drug developers are piloting or actively using AI tools. However, more than one-third of organizations remain cautious, unsure whether current AI capabilities are mature enough to justify investment or wide-scale adoption. To address these concerns, we spoke with Zach Weingarden, Director of AI Technology and Applications at TrialAssure, about the risks of waiting, the realities of today’s tools, and how to start effectively.

Is Now the Time for Pharma and Biotech to Act with AI or Should the Industry Wait for a Better Model? 

by Zach Weingarden | October 2025

Posted in Blog
Read More
TrialAssure & Certara Joint Webinar: Authoring Clinical Documents with Downstream Regulatory Requirements in Mind

New Webinar Announced on Stronger Clinical Document Authoring Workflows with Certara & TrialAssure

by Don McLean | September 2025

Posted in Blog, News
Read More
Scalable Medical Writing AI

The First Step Toward Scalable Medical Writing AI

by Don McLean | July 2025

Posted in Blog
Read More
Get in Touch

Looking to streamline your clinical trial disclosure and transparency efforts?

TrialAssure is ready to help your organization embark on a Transparency Transformation!

To learn more about the TrialAssure Transparency Suite, specific products, or our company, contact us below.

Yes, please send me more information about TrialAssure.